PMID- 22832952
OWN - NLM
STAT- MEDLINE
DCOM- 20130304
LR  - 20220129
IS  - 2158-3188 (Electronic)
IS  - 2158-3188 (Linking)
VI  - 2
IP  - 5
DP  - 2012 May 1
TI  - Neurotrophic gene polymorphisms and response to psychological therapy.
PG  - e108
LID - 10.1038/tp.2012.33 [doi]
AB  - Therapygenetics, the study of genetic determinants of response to psychological 
      therapies, is in its infancy. Here, we investigate whether single-nucleotide 
      polymorphisms in nerve growth factor (NGF) (rs6330) and brain-derived 
      neutrotrophic factor (BDNF) (rs6265) genes predict the response to cognitive 
      behaviour therapy (CBT). Neurotrophic genes represent plausible candidate genes: 
      they are implicated in synaptic plasticity, response to stress, and are widely 
      expressed in brain areas involved in mood and cognition. Allelic variation at 
      both loci has shown associations with anxiety-related phenotypes. A sample of 374 
      anxiety-disordered children with white European ancestry was recruited from 
      clinics in Reading, UK, and in Sydney, Australia. Participants received 
      manualised CBT treatment and DNA was collected from buccal cells using cheek 
      swabs. Treatment response was assessed at post-treatment and follow-up time 
      points. We report first evidence that children with one or more copies of the T 
      allele of NGF rs6330 were significantly more likely to be free of their primary 
      anxiety diagnosis at follow-up (OR = 0.60 (0.42-0.85), P = 0.005). These effects 
      remained even when other clinically relevant covariates were accounted for (OR = 
      0.62 (0.41-0.92), P = 0.019). No significant associations were observed between 
      BDNF rs6265 and response to psychological therapy. These findings demonstrate 
      that knowledge of genetic markers has the potential to inform clinical treatment 
      decisions for psychotherapeutic interventions.
FAU - Lester, K J
AU  - Lester KJ
AD  - King's College London, MRC Social, Genetic and Developmental Psychiatry Centre, 
      Institute of Psychiatry, London, UK. kathryn.lester@kcl.ac.uk
FAU - Hudson, J L
AU  - Hudson JL
FAU - Tropeano, M
AU  - Tropeano M
FAU - Creswell, C
AU  - Creswell C
FAU - Collier, D A
AU  - Collier DA
FAU - Farmer, A
AU  - Farmer A
FAU - Lyneham, H J
AU  - Lyneham HJ
FAU - Rapee, R M
AU  - Rapee RM
FAU - Eley, T C
AU  - Eley TC
LA  - eng
GR  - G0802326/MRC_/Medical Research Council/United Kingdom
GR  - GU601020/MRC_/Medical Research Council/United Kingdom
GR  - G0601874/MRC_/Medical Research Council/United Kingdom
GR  - G0601020/MRC_/Medical Research Council/United Kingdom
GR  - PB-PG-0107-12042/DH_/Department of Health/United Kingdom
GR  - G0901874/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120501
PL  - United States
TA  - Transl Psychiatry
JT  - Translational psychiatry
JID - 101562664
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (SLC6A4 protein, human)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
MH  - Adolescent
MH  - *Alleles
MH  - Anxiety Disorders/*genetics/*therapy
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Case-Control Studies
MH  - Child
MH  - *Cognitive Behavioral Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Expression/genetics
MH  - Genetic Association Studies
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Nerve Growth Factor/*genetics
MH  - Neuronal Plasticity/genetics
MH  - Phenotype
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Prognosis
MH  - Serotonin Plasma Membrane Transport Proteins/genetics
MH  - Treatment Outcome
PMC - PMC3365252
EDAT- 2012/07/27 06:00
MHDA- 2013/03/05 06:00
PMCR- 2012/05/01
CRDT- 2012/07/27 06:00
PHST- 2012/07/27 06:00 [entrez]
PHST- 2012/07/27 06:00 [pubmed]
PHST- 2013/03/05 06:00 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - tp201233 [pii]
AID - 10.1038/tp.2012.33 [doi]
PST - epublish
SO  - Transl Psychiatry. 2012 May 1;2(5):e108. doi: 10.1038/tp.2012.33.